Showing results (11-20 of 125) with videos related to

Sort By:
Pageof 13
Chemical & Pharmaceutical Bulletin|June 10, 2004
The first example of the stereoselective synthesis of 7 beta-carbamoyl-4,5alpha-epoxymorphinan via a novel and reactive gamma-lactoneHideaki Fujii, Noriyuki Hirano, Hiromi Uchiro, et al.
Surgery Today|July 21, 2011
Indocyanine green fluorescence monitoring of perineal wound contamination in abdominoperineal resection: a preliminary reportToshiyuki Kitai, Masahiro Kawashima, Hideaki Fujii, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 20, 2015
Dipeptidyl peptidase-4 greatly contributes to the hydrolysis of vildagliptin in human liverMitsutoshi Asakura, Hideaki Fujii, Koichiro Atsuda, et al.
World Journal of Surgery|April 25, 2007
Surgical resection of hilar cholangiocarcinoma: analysis of survival and postoperative complicationsSuguru Hasegawa, Iwao Ikai, Hideaki Fujii, et al.
Scientific Reports|October 21, 2016
Vildagliptin and its metabolite M20.7 induce the expression of S100A8 and S100A9 in human hepatoma HepG2 and leukemia HL-60 cellsMitsutoshi Asakura, Fumika Karaki, Hideaki Fujii, et al.
Behavioural Brain Research|December 6, 2016
Effects of repeated treatment with a delta opioid receptor agonist KNT-127 on hyperemotionality in olfactory-bulbectomized ratsLeo Gotoh, Akiyoshi Saitoh, Misa Yamada, et al.
Bioorganic & Medicinal Chemistry Letters|July 24, 2012
Investigation of 7-benzylidenenaltrexone derivatives as resistance reverser for chloroquine-resistant Plasmodium chabaudiYoshinori Miyata, Hideaki Fujii, Yuka Uenohara, et al.
Bioorganic & Medicinal Chemistry Letters|July 19, 2011
Opioid δ₁ receptor antagonist 7-benzylidenenaltrexone as an effective resistance reverser for chloroquine-resistant Plasmodium chabaudiYoshinori Miyata, Hideaki Fujii, Yumiko Osa, et al.
Pageof 13